Version July 2025
| Product name | Half-life (hours)* | Volume of distribution¶ | Characteristics |
| Standard half-life products | |||
| Advate | 9 to 12 | 0.5 | Recombinant |
| Hemofil M | 15 | 0.5 | Plasma-derived; mAb-purified |
| Kogenate FS | 11 to 15 | 0.5 | Recombinant |
| Koate (previously called Koate DVI) | 16 | 0.5 | Plasma-derived; chromatography-purified |
| Kovaltry | 12 to 14 | 0.5 | Recombinant |
| Novoeight | 8 to 12 | 0.5 | Recombinant |
| Nuwiq | 12 to 17 | 0.5 | Recombinant |
| Recombinate | 15 | 0.5 | Recombinant |
| Xyntha | 8 to 11 | 0.5 | Recombinant |
| Longer-lasting products | |||
| Adynovate | 13 to 16 | 0.5 | Recombinant; PEGylated |
| Afstyla | 10 to 14 | 0.5 | Recombinant; single chain |
| Altuviiio | 40 to 48 | Age 1 to 11 years: 0.5 Age 12 to 17 years: 0.44 Age ≥18 years: 0.38 | Recombinant; Fc-VWF-XTEN fusion |
| Eloctate | 13 to 20 | 0.5 | Recombinant; Fc fusion |
| Esperoct | 17 to 22 | 0.5 | Recombinant; glycoPEGylated |
| JiviΔ | 17 to 21 | 0.5 | Recombinant; PEGylated |
This table is intended as a guide for rapid identification of the product the patient is using and its characteristics and should not be used to select a product or calculate dosing. Refer to prescribing information in the product insert and to UpToDate for the use of factor replacement in patients with hemophilia. The plasma-derived products listed here are ultra-high purity (mAb-purified) or high purity (chromatography-purified).
Non-factor products are also available for individuals with hemophilia A (emicizumab, fitusiran, marstacimab); refer to UpToDate for details.
Fc: fragment crystallizable; FS: formulated with sucrose; mAb: monoclonal antibody; PEG: polyethylene glycol; VWF: von Willebrand factor; XTEN: half-life extension polypeptides.
* Half-lives are approximate. Half-lives are generally shorter for children than adults when assessed in pharmacokinetic studies. The half-life of factor VIII products without modifications to extend half-life is considered to be approximately 12 hours. The half-life should be determined for the individual patient. Refer to product information and institutional guidelines for additional dosing and monitoring information.
¶ Volumes of distribution are approximate. They are equal to the reciprocal of recovery values listed in United States prescribing information.
Δ 12 years and older.
